Roche's Co-Exclusive License for PI3K Marker Will Aid in Personalization of Genentech Drugs

Roche announced this week that the co-exclusive license for the biomarker would allow it to develop real-time and endpoint PCR assays to detect mutations in the PI3K oncogene, which would aid its subsidiary Genentech in the development of several investigational drug candidates.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.